Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
25.62
+3.16 (14.07%)
Mar 9, 2026, 3:11 PM EDT - Market open
Lyell Immunopharma Employees
Lyell Immunopharma had 300 employees as of December 31, 2024. The number of employees increased by 76 or 33.93% compared to the previous year.
Employees
300
Change (1Y)
76
Growth (1Y)
33.93%
Revenue / Employee
$137
Profits / Employee
-$1,085,533
Market Cap
544.27M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 300 | 76 | 33.93% |
| Dec 31, 2023 | 224 | -50 | -18.25% |
| Dec 31, 2022 | 274 | 55 | 25.11% |
| Dec 31, 2021 | 219 | 29 | 15.26% |
| Dec 31, 2020 | 190 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Rocket Pharmaceuticals | 202 |
| Entrada Therapeutics | 152 |
| Century Therapeutics | 150 |
| Kyverna Therapeutics | 129 |
| Lexeo Therapeutics | 61 |
| Altimmune | 59 |
| Zevra Therapeutics | 59 |
LYEL News
- 7 hours ago - Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer - GlobeNewsWire
- 2 days ago - Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 14 days ago - Lyell Immunopharma Announces Participation in March Investor Conferences - GlobeNewsWire
- 25 days ago - Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma - GlobeNewsWire
- 2 months ago - Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data - Seeking Alpha
- 3 months ago - Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition - GlobeNewsWire
- 4 months ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 - GlobeNewsWire
- 4 months ago - Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer - GlobeNewsWire